胃癌腹膜转移的分子生物学与免疫学
Molecular biology and immunology of gastric cancer peritoneal metastasis.
作者信息
Yao Xiaodan, Ajani Jaffer A, Song Shumei
机构信息
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Transl Gastroenterol Hepatol. 2020 Oct 5;5:57. doi: 10.21037/tgh.2020.02.08. eCollection 2020.
Abstract
Peritoneal metastases occur in 55-60% of patients with gastric cancer (GC) and are associated with a 2% 5-year overall survival rate. There are limited treatment options for these patients, and no targeted therapy or immunotherapy is available. Rational therapeutic targets remain to be found. In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signaling pathways as well as cellular immunity involved in the peritoneal metastasis of GC. We also suggest potential novel strategies for improving the outcomes of GC patients with peritoneal metastasis.
摘要
55%-60%的胃癌（GC）患者会发生腹膜转移，其5年总生存率仅为2%。这些患者的治疗选择有限，且尚无靶向治疗或免疫治疗方法。合理的治疗靶点仍有待发现。在本综述中，我们展示了已发表的文献以及我们自己在分子生物学方面的最新经验，以确定参与GC腹膜转移的重要分子、信号通路以及细胞免疫。我们还提出了改善GC腹膜转移患者预后的潜在新策略。
相似文献
1
Molecular biology and immunology of gastric cancer peritoneal metastasis.胃癌腹膜转移的分子生物学与免疫学
Transl Gastroenterol Hepatol. 2020 Oct 5;5:57. doi: 10.21037/tgh.2020.02.08. eCollection 2020.
2
Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment.食管癌腹膜转移癌的区域免疫治疗：重塑适应性不良肿瘤环境的新兴策略
Cancers (Basel). 2023 Oct 23;15(20):5107. doi: 10.3390/cancers15205107.
3
Epithelial-mesenchymal transition in gastric cancer.胃癌中的上皮-间质转化
Am J Transl Res. 2015 Nov 15;7(11):2141-58. eCollection 2015.
4
Zic1 suppresses gastric cancer metastasis by regulating Wnt/β-catenin signaling and epithelial-mesenchymal transition.Zic1 通过调控 Wnt/β-catenin 信号通路和上皮-间充质转化抑制胃癌转移。
FASEB J. 2020 Feb;34(2):2161-2172. doi: 10.1096/fj.201901372RR. Epub 2020 Jan 2.
5
CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.癌胚抗原相关细胞黏附分子6通过PI3K/AKT信号通路诱导上皮-间质转化，从而促进胃癌的侵袭和转移。
PLoS One. 2014 Nov 14;9(11):e112908. doi: 10.1371/journal.pone.0112908. eCollection 2014.
6
Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer.恶性腹水衍生的外泌体促进腹膜肿瘤细胞播散，并揭示晚期胃癌中独特的 miRNA 特征。
Cancer Lett. 2019 Aug 10;457:142-150. doi: 10.1016/j.canlet.2019.04.034. Epub 2019 May 8.
7
Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin.结直肠癌同时合并腹膜转移和肝转移患者的发病率、预后和治疗选择。
Dis Colon Rectum. 2013 Dec;56(12):1373-80. doi: 10.1097/DCR.0b013e3182a62d9d.
8
Research progress of epithelial-mesenchymal transformation-related transcription factors in peritoneal metastases.上皮-间质转化相关转录因子在腹膜转移中的研究进展
J Cancer. 2024 Aug 19;15(16):5367-5375. doi: 10.7150/jca.98409. eCollection 2024.
9
microRNA-33a prevents epithelial-mesenchymal transition, invasion, and metastasis of gastric cancer cells through the Snail/Slug pathway.microRNA-33a 通过 Snail/Slug 通路抑制胃癌细胞上皮间质转化、侵袭和转移。
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G147-G160. doi: 10.1152/ajpgi.00284.2018. Epub 2019 Apr 3.
10
MTMR2 promotes invasion and metastasis of gastric cancer via inactivating IFNγ/STAT1 signaling.MTMR2 通过抑制 IFNγ/STAT1 信号通路促进胃癌的侵袭和转移。
J Exp Clin Cancer Res. 2019 May 21;38(1):206. doi: 10.1186/s13046-019-1186-z.
引用本文的文献
1
Emerging trends of the tumor microenvironment in peritoneal malignancies (2010-2024): a visualization analysis.腹膜恶性肿瘤中肿瘤微环境的新趋势（2010 - 2024年）：可视化分析
Front Oncol. 2025 Jun 4;15:1515476. doi: 10.3389/fonc.2025.1515476. eCollection 2025.
2
The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.胃癌患者腹膜转移的预后价值：一项基于全国人群的研究。
EClinicalMedicine. 2025 Feb 13;81:103109. doi: 10.1016/j.eclinm.2025.103109. eCollection 2025 Mar.
3
CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases.肿瘤微环境中癌相关成纤维细胞与巨噬细胞的相互作用决定了胃癌腹膜转移对免疫检查点阻断的反应。
Gut. 2025 Feb 6;74(3):350-363. doi: 10.1136/gutjnl-2024-333617.
4
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.针对腹腔转移癌的白细胞介素-6 治疗方法。
J Transl Med. 2024 Apr 30;22(1):402. doi: 10.1186/s12967-024-05205-8.
5
Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis.PD-L1表达在胃癌腹膜转移患者中的预后意义
Biomedicines. 2023 Jul 15;11(7):2003. doi: 10.3390/biomedicines11072003.
6
Identification of Novel Prognostic Biomarkers That are Associated with Immune Microenvironment Based on GABA-Related Molecular Subtypes in Gastric Cancer.基于胃癌中GABA相关分子亚型鉴定与免疫微环境相关的新型预后生物标志物
Pharmgenomics Pers Med. 2023 Jun 28;16:665-679. doi: 10.2147/PGPM.S411862. eCollection 2023.
7
Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.腹膜癌的免疫治疗：挑战与预期结果
Cancers (Basel). 2023 Apr 20;15(8):2383. doi: 10.3390/cancers15082383.
8
A novel small molecule RK-019 inhibits -amplification gastric cancer cell proliferation and induces apoptosis and .一种新型小分子RK-019抑制胃癌细胞增殖并诱导凋亡。
Front Pharmacol. 2022 Sep 21;13:998199. doi: 10.3389/fphar.2022.998199. eCollection 2022.
9
The immune microenvironment in gastric adenocarcinoma.胃腺癌的免疫微环境。
Nat Rev Gastroenterol Hepatol. 2022 Jul;19(7):451-467. doi: 10.1038/s41575-022-00591-0. Epub 2022 Mar 14.
10
Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy.预后营养指数对接受纳武利尤单抗单药治疗的晚期胃癌腹膜转移患者的临床影响
Chonnam Med J. 2022 Jan;58(1):24-28. doi: 10.4068/cmj.2022.58.1.24. Epub 2022 Jan 25.
本文引用的文献
1
Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer.全基因组表达谱分析鉴定出一种基于新型微小RNA的标志物，用于检测胃癌患者的腹膜转移。
Ann Surg. 2021 Nov 1;274(5):e425-e434. doi: 10.1097/SLA.0000000000003647.
2
Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.嵌合抗原受体 T 细胞治疗实体瘤的临床研究：经验总结与未来方向。
Pharmacol Ther. 2020 Jan;205:107419. doi: 10.1016/j.pharmthera.2019.107419. Epub 2019 Oct 16.
3
Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites.腹水中外泌体miR-181b-5p表达下调可作为胃癌相关恶性腹水的潜在诊断生物标志物。
J Gastric Cancer. 2019 Sep;19(3):301-314. doi: 10.5230/jgc.2019.19.e27. Epub 2019 Aug 28.
4
The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.新型双特异性Trop2/PD-L1嵌合抗原受体T细胞对胃癌的杀伤作用
Am J Cancer Res. 2019 Aug 1;9(8):1846-1856. eCollection 2019.
5
Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer.CEACAM1 的缺失与胃癌患者的预后不良和腹膜扩散有关。
Sci Rep. 2019 Sep 3;9(1):12702. doi: 10.1038/s41598-019-49230-w.
6
MicroRNA‑140 suppresses Helicobacter pylori‑positive gastric cancer growth by enhancing the antitumor immune response.MicroRNA-140 可通过增强抗肿瘤免疫反应抑制幽门螺杆菌阳性胃癌的生长。
Mol Med Rep. 2019 Sep;20(3):2484-2492. doi: 10.3892/mmr.2019.10475. Epub 2019 Jul 8.
7
Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer.胃癌新辅助化疗后多种检查点分子表达变化及肿瘤免疫细胞浸润情况
J Cancer. 2019 Jun 2;10(12):2754-2763. doi: 10.7150/jca.31755. eCollection 2019.
8
Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.对胃腺癌腹膜转移进行的多指标分析鉴定了新的靶点和分子亚型，这些靶点和分子亚型可预测治疗反应。
Gut. 2020 Jan;69(1):18-31. doi: 10.1136/gutjnl-2018-318070. Epub 2019 Jun 6.
9
miR-383 Inhibited the Cell Cycle Progression of Gastric Cancer Cells via Targeting Cyclin E2.miR-383 通过靶向细胞周期蛋白 E2 抑制胃癌细胞的细胞周期进程。
DNA Cell Biol. 2019 Aug;38(8):849-856. doi: 10.1089/dna.2019.4624. Epub 2019 Jun 6.
10
MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer.微小RNA-198通过直接抑制胃癌中的FGFR1来抑制细胞增殖并诱导细胞凋亡。
Biosci Rep. 2019 Jun 10;39(6). doi: 10.1042/BSR20181258. Print 2019 Jun 28.
Zotero 插件